Delivery Order SPE2DB24D1007-SPE2DB25FCDAN
Award Date 8/29/25
Potential Completion Date 9/2/25
Potential Value $13K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,219.89 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 25, 2025. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, asthma, and...
- The Defense Logistics Agency awarded a delivery order valued at $37,021.94 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 28, 2025, with an ultimate completion date of August 29, 2025. This competitively awarded, firm fixed-price contract with no set-aside designation will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat atopic dermatitis, asthma, and other...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Dupixent 300 mg/2 ml pens with a ceiling value of $43,275.69. This firm fixed-price, non-set-aside contract is scheduled for completion by August 13, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat conditions including atopic dermatitis, eczema, asthma, and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $3,418.92. This non-competitive, firm fixed-price delivery order is scheduled for completion by August 12, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and other...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $74,194.57 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and specifies performance at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat various allergic and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at approximately $42,064 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens. This firm fixed-price delivery order, issued on August 25, 2025, represents a competitively awarded, non-set-aside contract with an ultimate completion date of August 26, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order on July 22, 2025, for Dupixent 300 mg/2 mL pens with a ceiling value of $14,474.85 under a firm fixed price arrangement. The award, which is not set-aside and competitively awarded, is scheduled for completion by July 23, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $217,423.50 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 28, 2025. This firm fixed-price delivery order, which carries an ultimate completion date of July 29, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its Pennsylvania...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $59,336.93 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens (2 mL). The contract, awarded on August 8, 2025, with an ultimate completion date of August 11, 2025, utilizes firm fixed pricing with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is performing the work at its corporate office location. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Dupixent 300 mg/2 mL pens with a ceiling value of $46,237.16. This firm fixed-price delivery order, with an ultimate completion date of July 31, 2025, represents a competitively awarded, non-set-aside procurement executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026....